Podcasts about inlyta

Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab (Bavencio) plus axitinib (Inlyta) for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.

Dr. Scot Ebbinghaus from Merck Research Laboratories discusses the recent European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) positive opinion on Merck's KEYTRUDA® (pembrolizumab) in combination with Inlyta (axitinib) as first-line treatment for advanced renal cell carcinoma. Opinion granted based on data from the Phase 3 KEYNOTE-426 Trial. #RenalCellCarcinoma #AdvancedRenalCellCarcinoma #AdvancedRenalCellCarcinomaTreatment Visit our website www.healtprofessionalradio.com.au Follow us on our social media channels Facebook: https://www.facebook.com/hprfm/ Twitter: https://twitter.com/HealthProRadio Google+: https://plus.google.com/+HealthProfes... Pinterest: https://www.pinterest.com/HealthProRa... Linkedin: https://www.linkedin.com/company/heal... Instagram: https://www.instagram.com/healthprofe... Subscribe to our podcast channels Soundcloud: https://soundcloud.com/healthprofessi... Itunes: https://itunes.apple.com/nz/podcast/h... Support us on Patreon https://www.patreon.com/HPR

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.

Today in FirstWord: